Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT03842696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03842696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 4, 2020
Completion date
April 1, 2026
Enrollment
43 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia in remission, chronic myelogenous leukemia - chronic phase, chronic myelogenous leukemia, accelerated phase, chronic myelogenous leukemia, blastic phase, diffuse large b cell lymphoma, follicular lymphoma, graft vs host disease, graft-versus-host-disease, hematologic diseases, mantle cell lymphoma, myelodysplastic syndromes, non hodgkin lymphoma